Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFONAMIDES DUPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFONAMIDES DUPLEX.
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE vs SULFONAMIDES DUPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
None Documented
None Documented
Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic